The Scottish Medicines Consortium has announce it has approved ocrelizumab (Ocrevus) for the treatment of relapsing remitting multiple sclerosis (RRMS).
The drug was approved by NICE for the treatment of RRMS patients in England back in June 2018, after it was previously turned down in April 2018 for not being cost effective.
Clinical trial results show that ocrelizumab reduces the number of relapses and slows disability progression compared with interferon beta-1a for people with RRMS.
Ocrelizumab offers another disease modifying therapy treatment option for MS patients in Scotland. However, the Scottish Medicines Consortium says it should only be prescribed to patients who are experiencing relapses or have MRI evidence of new areas of MS activity, and are unable or unwilling to take Lemtrada (alemtuzumab).
The drug has also been put forward for the treatment of primary progressive multiple sclerosis (PPMS) in England and patients continue to wait and see if it manages to get the go-ahead, after the announcement of its approval from NICE was delayed in October 2018.
There are currently no approved treatments of PPMS. However, NICE has acknowledged that the condition can have a substantial impact on a person’s life, as well as affecting their families.
At this current time the Scottish Medicines Consortium has not reviewed ocrelizumab as an NHS treatment for PPMS in Scotland.
Source: MS-UK, 13/12/18